Atticus Wealth Management LLC lowered its stake in shares of Abbott Laboratories (NYSE: ABT – Get Rating) by 9.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 3,204 shares of the healthcare product maker’s stock after selling 353 shares during the quarter. Atticus Wealth Management LLC’s holdings in Abbott Laboratories were worth $ 379,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Jackson Wealth Management LLC boosted its holdings in Abbott Laboratories by 2.1% during the 3rd quarter. Jackson Wealth Management LLC now owns 34,368 shares of the healthcare product maker’s stock valued at $ 25,000 after acquiring an additional 722 shares during the period. Blue Bell Private Wealth Management LLC purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth $ 30,000. Delos Wealth Advisors LLC lifted its holdings in shares of Abbott Laboratories by 100.9% in the 4th quarter. Delos Wealth Advisors LLC now owns 231 shares of the healthcare product maker’s stock worth $ 33,000 after buying an additional 116 shares during the period. Retirement Group LLC lifted its holdings in shares of Abbott Laboratories by 1,125.0% in the 4th quarter. Retirement Group LLC now owns 245 shares of the healthcare product maker’s stock worth $ 34,000 after buying an additional 225 shares during the period. Finally, Lumature Wealth Partners LLC lifted its holdings in shares of Abbott Laboratories by 65.4% in the 4th quarter. Lumature Wealth Partners LLC now owns 301 shares of the healthcare product maker’s stock worth $ 42,000 after buying an additional 119 shares during the period. Institutional investors own 73.46% of the company stock.
ABT has been the subject of several research reports. BTIG Research lowered their target price on Abbott Laboratories from $ 140.00 to $ 130.00 and set a “buy” rating for the company in a report on Friday. Raymond James decreased their price objective on Abbott Laboratories from $ 143.00 to $ 135.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. Wells Fargo & Company decreased their price objective on Abbott Laboratories from $ 155.00 to $ 150.00 and set an “overweight” rating for the company in a research note on Friday, April 8th. StockNews.com initiated coverage on Abbott Laboratories in a research note on Thursday, March 31st. They set a “strong-buy” rating for the company. Finally, Bank of America initiated coverage on Abbott Laboratories in a research report on Tuesday, March 1st. They set a “buy” rating and a $ 140.00 target price on the stock. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $ 139.64.
Shares of ABT stock opened at $ 109.45 on Friday. The stock’s 50-day simple moving average is $ 112.55 and its 200-day simple moving average is $ 121.22. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.40 and a current ratio of 1.85. The firm has a market capitalization of $ 191.64 billion, a PE ratio of 25.39, a P / E / G ratio of 3.95 and a beta of 0.73. Abbott Laboratories has a fifty-two week low of $ 101.24 and a fifty-two week high of $ 142.60.
Abbott Laboratories (NYSE: ABT – Get Rating) last announced its quarterly earnings data on Wednesday, April 20th. The healthcare product maker reported $ 1.73 earnings per share for the quarter, beating analysts’ consensus estimates of $ 1.47 by $ 0.26. The business had revenue of $ 11.90 billion for the quarter, compared to analyst estimates of $ 11 billion. Abbott Laboratories had a return on equity of 28.72% and a net margin of 17.35%. The company revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the company earned $ 1.32 earnings per share. Sell-side analysts forecast that Abbott Laboratories will post 4.84 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be issued a $ 0.47 dividend. This represents a $ 1.88 dividend on an annualized basis and a dividend yield of 1.72%. The ex-dividend date is Thursday, July 14th. Abbott Laboratories’s dividend payout ratio is presently 43.62%.
In related news, Director Daniel J. Starks sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $ 113.22, for a total transaction of $ 5,661,000.00. Following the sale, the director now directly owns 6,973,500 shares of the company stock, valued at $ 789,539,670. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Randel William Woodgrift sold 24,000 shares of the firm’s stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $ 113.00, for a total value of $ 2,712,000.00. Following the sale, the senior vice president now directly owns 47,854 shares in the company, valued at $ 5,407,502. The disclosure for this sale can be found here. 0.52% of the stock is owned by company insiders.
Abbott Laboratories Profile: (Get Rating)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Receive News & Ratings for Abbott Laboratories Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.